Your browser doesn't support javascript.
loading
Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression.
Olson, Heather E; Kelly, McKenna; LaCoursiere, Christopher M; Pinsky, Rebecca; Tambunan, Dimira; Shain, Catherine; Ramgopal, Sriram; Takeoka, Masanori; Libenson, Mark H; Julich, Kristina; Loddenkemper, Tobias; Marsh, Eric D; Segal, Devorah; Koh, Susan; Salman, Michael S; Paciorkowski, Alex R; Yang, Edward; Bergin, Ann M; Sheidley, Beth Rosen; Poduri, Annapurna.
Afiliación
  • Olson HE; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Kelly M; Harvard Medical School, Boston, MA.
  • LaCoursiere CM; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Pinsky R; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Tambunan D; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Shain C; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Ramgopal S; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Takeoka M; Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA.
  • Libenson MH; Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Julich K; Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Loddenkemper T; Harvard Medical School, Boston, MA.
  • Marsh ED; Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Segal D; Harvard Medical School, Boston, MA.
  • Koh S; Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Salman MS; Department of Neurology, Boston Children's Hospital, Boston, MA.
  • Paciorkowski AR; Harvard Medical School, Boston, MA.
  • Yang E; Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, MA.
  • Bergin AM; Neurogenetics Program, Department of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Sheidley BR; Department of Neurology, Rutgers New Jersey Medical School, Newark, NJ.
  • Poduri A; Department of Pediatrics, Division of Pediatric Neurology, Weill Cornell Medicine, New York, NY.
Ann Neurol ; 81(3): 419-429, 2017 Mar.
Article en En | MEDLINE | ID: mdl-28133863
ABSTRACT

OBJECTIVE:

We sought to identify genetic causes of early onset epileptic encephalopathies with burst suppression (Ohtahara syndrome and early myoclonic encephalopathy) and evaluate genotype-phenotype correlations.

METHODS:

We enrolled 33 patients with a referral diagnosis of Ohtahara syndrome or early myoclonic encephalopathy without malformations of cortical development. We performed detailed phenotypic assessment including seizure presentation, electroencephalography, and magnetic resonance imaging. We confirmed burst suppression in 28 of 33 patients. Research-based exome sequencing was performed for patients without a previously identified molecular diagnosis from clinical evaluation or a research-based epilepsy gene panel.

RESULTS:

In 17 of 28 (61%) patients with confirmed early burst suppression, we identified variants predicted to be pathogenic in KCNQ2 (n = 10), STXBP1 (n = 2), SCN2A (n = 2), PNPO (n = 1), PIGA (n = 1), and SEPSECS (n = 1). In 3 of 5 (60%) patients without confirmed early burst suppression, we identified variants predicted to be pathogenic in STXBP1 (n = 2) and SCN2A (n = 1). The patient with the homozygous PNPO variant had a low cerebrospinal fluid pyridoxal-5-phosphate level. Otherwise, no early laboratory or clinical features distinguished the cases associated with pathogenic variants in specific genes from each other or from those with no prior genetic cause identified.

INTERPRETATION:

We characterize the genetic landscape of epileptic encephalopathy with burst suppression, without brain malformations, and demonstrate feasibility of genetic diagnosis with clinically available testing in >60% of our cohort, with KCNQ2 implicated in one-third. This electroclinical syndrome is associated with pathogenic variation in SEPSECS. Ann Neurol 2017;81419-429.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Espasmos Infantiles / Canal de Potasio KCNQ2 / Aminoacil-ARNt Sintetasas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: Ann Neurol Año: 2017 Tipo del documento: Article País de afiliación: Marruecos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Espasmos Infantiles / Canal de Potasio KCNQ2 / Aminoacil-ARNt Sintetasas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: Ann Neurol Año: 2017 Tipo del documento: Article País de afiliación: Marruecos